

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1646970
<b>Application Number:</b>	10649413
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5257
<b>Title of Invention:</b>	Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer
<b>First Named Inventor/Applicant Name:</b>	Axel Ullrich
<b>Customer Number:</b>	23460
<b>Filer:</b>	Rachel Jean Mejdrich/Loraine Perry
<b>Filer Authorized By:</b>	Rachel Jean Mejdrich
<b>Attorney Docket Number:</b>	224160
<b>Receipt Date:</b>	02-APR-2007
<b>Filing Date:</b>	27-AUG-2003
<b>Time Stamp:</b>	17:56:50
<b>Application Type:</b>	Utility

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 630
RAM confirmation Number	934
Deposit Account	121216

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:  
Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Fee Worksheet (PTO-06)	ROATransmittal.pdf	129216	no	1
<b>Warnings:</b>					
<b>Information:</b>					
2	Amendment - After Non-Final Rejection	ROA.pdf	709343	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	Information Disclosure Statement (IDS) Filed	IDS.pdf	419588	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	Information Disclosure Statement (IDS) Filed	Form1449.pdf	175307	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	NPL Documents	Bange-CancerResearch-2002.pdf	258306	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	DaCostaAndrade-ExpMolPat hol-2007.pdf	719803	no	5
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Spinola-JClinOncol-2005.pdf	137344	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Streit-IntJ Cancer-2004.pdf	422144	no	5
<b>Warnings:</b>					
<b>Information:</b>					

9	NPL Documents	Thussbas-JClinOncol-2006.pdf	844109	no	9
Warnings:					
Information:					
10	NPL Documents	Wang-ClinicalCancerRes-2004.pdf	530616	no	10
Warnings:					
Information:					
11	Fee Worksheet (PTO-06)	fee-info.pdf	8356	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			4354132		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**  
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**  
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**  
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.